Patents by Inventor Rein Sikut

Rein Sikut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
    Patent number: 9474800
    Abstract: The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: October 25, 2016
    Assignee: FIT Biotech OY
    Inventors: Kaja Kiiver, Rein Sikut, Urve Toots, Tarmo Mölder, Andres Männik, Mart Ustav, Katrin Kaldma
  • EXPRESSION VECTOR ENCODING ALPHAVIRUS REPLICASE AND THE USE THEREOF AS IMMUNOLOGICAL ADJUVANT
    Publication number: 20110171255
    Abstract: The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today.
    Type: Application
    Filed: May 22, 2009
    Publication date: July 14, 2011
    Applicant: Fit Biotech Oy
    Inventors: Kaja Kiiver, Rein Sikut, Urve Toots, Tarmo Mölder, Andres Männik, Mart Ustav, Katrin Kaldma